WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at three upcoming investor conferences:
Disc management will be participating in investor meetings during each of the above conferences, as well as the Jefferies Biotech on the Beach Summit in Miami, FL. The Jefferies meetings take place on Tuesday, March 11th.
Live webcasts of the corporate presentation and fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Christina Tartaglia
Precision AQ
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$55.86 |
Daily Change: | 2.89 5.46 |
Daily Volume: | 399,234 |
Market Cap: | US$1.930B |
May 07, 2025 April 29, 2025 February 27, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load